Spots Global Cancer Trial Database for Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment
Official Title: Phase II Trial of Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment
Study ID: NCT03536780
Conditions
Interventions
Study Description
Brief Summary: A Phase 2 trial of avelumab plus gemcitabine in advanced leiomyosarcoma as a second line treatment
Detailed Description:
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Dong-a University Hospital, Busan, , Korea, Republic of
Gachon University Gil Medical Center, Incheon, , Korea, Republic of
Seoul National University Bundang Hospital, Seongnam-si, , Korea, Republic of
Asan Medical Center, Seoul, , Korea, Republic of
Samsung Medical Center, Seoul, , Korea, Republic of
Seoul National University Hospital, Seoul, , Korea, Republic of
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
